I don’t want to stake out a strong position on “remdesivir is Never good to give a patient” but look, 30% reduction in time to recovery in severe patients, no mortality benefit, is not a cure.
-
Show this thread
-
Remdesivir is not gonna make it safe for everyone to go back to work. It’s just not that big an effect. And we desperately need an effect that big.
2 replies 2 retweets 16 likesShow this thread -
Except now, as
@MarkHoofnagle notes, remdesivir is “standard of care” & now every other drug has to prove noninferiority! Nice power grab, Gilead!1 reply 0 retweets 34 likesShow this thread -
This means “standard of care” is also bullshit, if you didn’t know. It’s a negotiation between power players, not a sober assessment of the science.
1 reply 7 retweets 62 likesShow this thread -
This is
#regulatorycapture in action. Remdesivir, from all I can see, was a reasonable drug to try against#COVID19. There are lots of other reasonable drugs to try. Only the ones with deep pockets and good political relationships will get approved.1 reply 13 retweets 45 likesShow this thread -
And then people will say “Science Says these are the good drugs and the others are bad” but never ask who determines *which* science gets done
1 reply 0 retweets 28 likesShow this thread -
What ordinary lay humans care about — can this drug save lives? can it make
#COVID19 close to harmless? — is not even being tested!!!1 reply 0 retweets 17 likesShow this thread -
“Hydroxychloroquine doesn’t have an RCT and remdesivir does!” Yes, true, and ALSO notice that hydroxychloroquine is a cheap generic so there’s nobody to *pay* for a big RCT.
3 replies 4 retweets 36 likesShow this thread -
And the public only knows about hydroxychloroquine because there’s this one doc with a bee in his bonnet about it (and he’s probably biased and sloppy and goes to the media too early and exaggerates.)
2 replies 0 retweets 21 likesShow this thread -
If it’s a cheap generic that *doesn’t* have a crazed fanboy, it’ll have even less apparent “success.” When was the last time you heard Discourse about indomethacin or niclosamide?
1 reply 0 retweets 31 likesShow this thread
If you don’t like that the “standard of care” is biased towards the interests of a handful of pharma companies...maybe the problem is that you need to be a hundred-billion-dollar company to run a clinical trial that satisfies today’s FDA?
-
-
Replying to @s_r_constantin
Is there any account of folks in positions of influence soberly realizing that the FDA can do more harm than good as a result of the pandemic?
1 reply 0 retweets 3 likes -
Replying to @maxefremov
The FDA has loosened many of its usual restrictions because of the pandemic. The concept of risk-benefit tradeoffs is, I expect, very familiar to them. “Deregulation can ever be good” is clearly a notion the Trump administration has heard of.
1 reply 0 retweets 4 likes - 28 more replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.